Angiotensin II and nitric oxide interaction.

Abstract:

:Nitric oxide degradation linked to endothelial dysfunction plays a central role in cardiovascular diseases. Superoxide producing enzymes such as NADPH oxidase and xanthine oxidase are responsible for NO degradation as they generate a variety of reactive oxygen species (ROS). Moreover, superoxide is rapidly degraded by superoxide dismutase to produce hydrogen peroxide leading to the uncoupling of NO synthase and production of increased amount of superoxide. Angiotensin II is an important stimulus of NADPH oxidase. Through its AT(1) receptor, Ang II stimulates the long-term increase of several membrane component of NADPH oxidase such as P(22) phox or nox-1 and causes an increased activity of NADPH oxidase with inactivation of NO leading to impaired endothelium-dependent vasorelaxation, vascular smooth muscle cell hypertrophy, proliferation and migration, extracellular matrix formation, thrombosis, cellular infiltration and inflammatory reaction. Several preclinical and clinical studies have now confirmed the involvement of the AT(1) receptor in endothelial dysfunction. It is proposed that the AT(2) receptor counterbalances the deleterious effect of the Ang II-induced AT(1) receptor stimulation through bradykinin and NOS stimulation. This mechanism could be especially relevant in pathological cases when the NADPH oxidase activity is blocked with an AT(1) receptor antagonist.

journal_name

Heart Fail Rev

journal_title

Heart failure reviews

authors

de Gasparo M

doi

10.1023/a:1020714518246

subject

Has Abstract

pub_date

2002-10-01 00:00:00

pages

347-58

issue

4

eissn

1382-4147

issn

1573-7322

journal_volume

7

pub_type

杂志文章,评审
  • Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients.

    abstract::There is ongoing controversy regarding the association between loop diuretics (LD), especially in high doses, and adverse clinical outcomes in outpatients with heart failure (HF). We performed a systematic review of the evidence for LD in outpatients with HF. We searched MEDLINE, EMBASE, and Cochrane Clinical Trial Co...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-09995-z

    authors: Kapelios CJ,Bonou Μ,Malliaras K,Athanasiadi E,Vakrou S,Skouloudi M,Masoura C,Barbetseas J

    更新日期:2020-06-21 00:00:00

  • Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings.

    abstract::Cor pulmonale is the condition in which the right ventricle undergoes morphological and/or functional changes due to diseases that affect the lungs, the pulmonary circulation, or the breathing process. Depending on the speed of onset of the pathological condition and subsequent effects on the right ventricle, it is po...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-10014-4

    authors: Mandoli GE,Sciaccaluga C,Bandera F,Cameli P,Esposito R,D'Andrea A,Evola V,Sorrentino R,Malagoli A,Sisti N,Nistor D,Santoro C,Bargagli E,Mondillo S,Galderisi M,Cameli M,Working group of Echocardiography of Italian Society

    更新日期:2020-08-29 00:00:00

  • In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.

    abstract::To determine and address medication non-adherence is important and may improve patient outcomes. Our aim was to perform a systematic review on the operationalization of adherence measures in patients with heart failure using claims data. We searched the MEDLINE, EMBASE, and Cochrane databases. A quality check of the f...

    journal_title:Heart failure reviews

    pub_type: 杂志文章

    doi:10.1007/s10741-017-9656-x

    authors: Krueger K,Griese-Mammen N,Schubert I,Kieble M,Botermann L,Laufs U,Kloft C,Schulz M

    更新日期:2018-01-01 00:00:00

  • Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.

    abstract::It is over 4 years since the Prospective Comparison of angiotensin receptor/neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was published in New England Journal of Medicine. The PARADIGM-HF trial was the one that contributed to the offici...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-019-09879-x

    authors: Książczyk M,Lelonek M

    更新日期:2020-05-01 00:00:00

  • Preconditioning in humans.

    abstract::Brief ischemia to the myocardium initiates a cascade of biochemical events in cardiac myocytes that protects the heart muscle during subsequent ischemic insults. This phenomenon is called ischemic preconditioning. If an acute myocardial infarction is preceded by preinfarction angina, it results in smaller infarction s...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-007-9037-y

    authors: Rezkalla SH,Kloner RA

    更新日期:2007-12-01 00:00:00

  • Emerging concepts in arrhythmogenic dilated cardiomyopathy.

    abstract::Dilated cardiomyopathy (DCM) represents one of the primary cardiomyopathies and may lead to heart failure and sudden death. Until recently, ventricular arrhythmias were considered to be a direct consequence of the systolic dysfunction of the left ventricle (LV) and guidelines for implantable cardioverter defibrillator...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-09933-z

    authors: Zegkos T,Panagiotidis T,Parcharidou D,Efthimiadis G

    更新日期:2020-02-13 00:00:00

  • Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.

    abstract::The prevalence of heart failure (HF) is increasing. A distinction is made between diastolic HF (preserved left ventricular ejection fraction (LVEF)) and systolic HF (reduced LVEF). Advanced glycation end-products (AGEs) are crystallized proteins that accumulate during ageing, but are particularly increased in patients...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-010-9225-z

    authors: Willemsen S,Hartog JW,Heiner-Fokkema MR,van Veldhuisen DJ,Voors AA

    更新日期:2012-03-01 00:00:00

  • (1)H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism.

    abstract::Magnetic resonance spectroscopy (MRS) is the only non-invasive, non-radiation-based technique for investigating the metabolism of living tissue. MRS of protons (1H-MRS), which provides the highest sensitivity of all MR-visible nuclei, is a method capable of detecting and quantifying specific cardiac biomolecules, such...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-012-9341-z

    authors: Faller KM,Lygate CA,Neubauer S,Schneider JE

    更新日期:2013-09-01 00:00:00

  • Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.

    abstract::Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of ...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-017-9647-y

    authors: Anfinogenova Y,Grakova EV,Shvedova M,Kopieva KV,Teplyakov AT,Popov SV

    更新日期:2018-05-01 00:00:00

  • Anticoagulation in heart failure: current status and future direction.

    abstract::Despite therapeutic advances, patients with worsening heart failure (HF) requiring hospitalization have unacceptably high post-discharge mortality and re-admission rates soon after discharge. Evidence suggests a hypercoagulable state is present in patients with HF. Although thromboembolism as a direct consequence of H...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-012-9343-x

    authors: Gheorghiade M,Vaduganathan M,Fonarow GC,Greene SJ,Greenberg BH,Liu PP,Massie BM,Mehra MR,Metra M,Zannad F,Cleland JG,van Veldhuisen DJ,Shah AN,Butler J

    更新日期:2013-11-01 00:00:00

  • Cardiotoxicity in HER2-positive breast cancer patients.

    abstract::Due to the recent advances in diagnosis and management of patients with HER2-positive breast cancer, especially through novel HER2-targeted agents, cardiotoxicity becomes an emerging problem. Although chemotherapy significantly increases survival, the risk of cardiovascular disease development is high and still undere...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-10072-8

    authors: Gonciar D,Mocan L,Zlibut A,Mocan T,Agoston-Coldea L

    更新日期:2021-01-06 00:00:00

  • Nutrition intervention in heart failure: should consumption of the DASH eating pattern be recommended to improve outcomes?

    abstract::Heart failure (HF) is a chronic, systemic disorder that presents a serious and growing public health problem due to its high prevalence, mortality, and cost of care. Due to the aging of the population and medical advances that prolong the life of HF patients, more effective, widespread strategies for improved HF manag...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-019-09781-6

    authors: Abu-Sawwa R,Dunbar SB,Quyyumi AA,Sattler ELP

    更新日期:2019-07-01 00:00:00

  • Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.

    abstract::Diabetes is a global epidemic and a leading cause of death with more than 422 million patients worldwide out of whom around 392 million alone suffer from type 2 diabetes (T2D). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel and effective drugs in managing glycemia of T2D patients. These inhibitors gained...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-017-9665-9

    authors: Kaplan A,Abidi E,El-Yazbi A,Eid A,Booz GW,Zouein FA

    更新日期:2018-05-01 00:00:00

  • Erythropoietin: a future therapy for failing hearts?

    abstract::Recently, it has been suggested that erythropoietin may be useful in the treatment of cardiovascular disease, particularly heart failure. This may be by improving microvascular blood supply and ventricular function through prevention of apoptosis and angiogenesis. Promising results were seen in animals but the few, li...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-011-9288-5

    authors: Tilling L,Clapp B

    更新日期:2012-05-01 00:00:00

  • Definition, epidemiology and registries of pulmonary hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a subcategory of pulmonary hypertension (PH) that comprises a group of disorders with similar pulmonary vascular pathology. Though PH is common, the estimated incidence of IPAH is 1-3 cases per million, making it a rare disease. The hemodynamic definition of PAH is a mean pulmo...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-015-9510-y

    authors: Awdish R,Cajigas H

    更新日期:2016-05-01 00:00:00

  • Effects of apelin on the cardiovascular system.

    abstract::Apelin is an endogenous peptide acting on the APJ receptor. It consists of several isoforms characterized by different numbers of amino acids. The number of amino acids in the active isoforms range from 36 to 12. Apelin-13 and, to a lesser extent, apelin-36 are considered the most active isoforms with the greatest act...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-015-9475-x

    authors: Folino A,Montarolo PG,Samaja M,Rastaldo R

    更新日期:2015-07-01 00:00:00

  • Personalised computational cardiology: Patient-specific modelling in cardiac mechanics and biomaterial injection therapies for myocardial infarction.

    abstract::Predictive computational modelling in biomedical research offers the potential to integrate diverse data, uncover biological mechanisms that are not easily accessible through experimental methods and expose gaps in knowledge requiring further research. Recent developments in computing and diagnostic technologies have ...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-016-9528-9

    authors: Sack KL,Davies NH,Guccione JM,Franz T

    更新日期:2016-11-01 00:00:00

  • The late phase of preconditioning and its natural clinical application--gene therapy.

    abstract::There is little doubt that the discovery of ischemic preconditioning (PC) has been one of the fundamental milestones in the field of ischemic biology in the past 20 years. The purpose of this article is to review the pathophysiology and molecular basis of the late phase of myocardial PC. The exploitation of late PC fo...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-007-9031-4

    authors: Bolli R,Li QH,Tang XL,Guo Y,Xuan YT,Rokosh G,Dawn B

    更新日期:2007-12-01 00:00:00

  • Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions.

    abstract::Heart failure is a complex clinical syndrome associated with a significant morbidity and mortality burden. Reductions in left ventricular (LV) function trigger adaptive mechanisms, leading to structural changes within the LV and the potential development of dyssynchronous ventricular activation. This is the substrate ...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-018-9734-8

    authors: Sieniewicz BJ,Gould J,Porter B,Sidhu BS,Teall T,Webb J,Carr-White G,Rinaldi CA

    更新日期:2019-01-01 00:00:00

  • Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a major health problem worldwide, with co-morbidities contributing to the overall severity and mortality of the disease. The incidence and prevalence of cardiovascular disease among COPD patients are high. Both disorders often co-exist, mainly due to smoking, but they al...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-017-9646-z

    authors: Petta V,Perlikos F,Loukides S,Bakakos P,Chalkias A,Iacovidou N,Xanthos T,Tsekoura D,Hillas G

    更新日期:2017-11-01 00:00:00

  • Pharmacological treatment of chronic heart failure.

    abstract::Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The ma...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-006-9482-z

    authors: Adorisio R,De Luca L,Rossi J,Gheorghiade M

    更新日期:2006-06-01 00:00:00

  • Clinical impact of oral antidiabetic medications in heart failure patients.

    abstract::Heart failure (HF) is a common complication in patients with type 2 diabetes and it is closely associated with high morbidity and mortality rate. The incidence of cardiovascular events in patients with diabetes is related to high levels of glycemia, expressed by increase of HbA1c levels. However, there is little evide...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-018-9669-0

    authors: Palazzuoli A,Ceccarelli E,Ruocco G,Nuti R

    更新日期:2018-05-01 00:00:00

  • Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications.

    abstract::Coronavirus disease 2019 (COVID-19) is due to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 which binds and enters the host cells through the angiotensin-converting enzyme (ACE)2. While the potential for benefit with the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and the risks from sto...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-10022-4

    authors: Triposkiadis F,Starling RC,Xanthopoulos A,Butler J,Boudoulas H

    更新日期:2020-09-01 00:00:00

  • Beta-blockers in heart failure: are pharmacological differences clinically important?

    abstract::Beta-blockers are not an homogeneous group of agents. Only three beta-blockers, carvedilol, bisoprolol and metoprolol succinate, have had favorable effects on prognosis in controlled clinical trials in the patients with chronic heart failure. However, pharmacological differences exist between them. Metoprolol and biso...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1023/B:HREV.0000046367.99002.a4

    authors: Metra M,Cas LD,di Lenarda A,Poole-Wilson P

    更新日期:2004-04-01 00:00:00

  • Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction.

    abstract::Recent cardiovascular outcome trials have highlighted the propensity of the antidiabetic agents, SGLT2 inhibitors (SGLT2is or -flozin drugs), to exert positive clinical outcomes in patients with cardiovascular disease at risk for major adverse cardiovascular events (MACEs). Of interest in cardiac diabetology is the ph...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-09996-y

    authors: Nashawi M,Sheikh O,Battisha A,Mir M,Chilton R

    更新日期:2020-06-24 00:00:00

  • New strategies for improving stem cell therapy in ischemic heart disease.

    abstract::Stem cell therapy is a promising approach to the treatment of ischemic heart disease via replenishing cell loss after myocardial infarction. Both preclinical studies and clinical trials have indicated that cardiac function improved consistently, but very modestly after cell-based therapy. This mainly attributed to low...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-016-9576-1

    authors: Huang P,Tian X,Li Q,Yang Y

    更新日期:2016-11-01 00:00:00

  • The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

    abstract::Diabetes and heart failure (HF) are both global epidemics with tremendous costs on society with increased rates of HF hospitalizations and worsened prognosis when co-existing, making it a significant "deadly duo." The evidence for pharmacological treatment of HF in patients with type 2 diabetes mellitus (T2DM) stems t...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-018-9685-0

    authors: Ofstad AP,Atar D,Gullestad L,Langslet G,Johansen OE

    更新日期:2018-05-01 00:00:00

  • Extracellular matrix-based biomaterials for cardiac regeneration and repair.

    abstract::The spectrum of ischemic heart diseases, encompassing acute myocardial infarction to heart failure, represents the leading cause of death worldwide. Although extensive progress in cardiovascular diagnoses and therapy has been made, the prevalence of the disease continues to increase. Cardiac regeneration has a promisi...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-020-09953-9

    authors: Li H,Bao M,Nie Y

    更新日期:2020-04-18 00:00:00

  • The role of myocardial viability in contemporary cardiac practice.

    abstract::Ischemic heart disease (IHD) remains the single most common cause of death worldwide. Ischemic cardiomyopathy is a major sequel of coronary artery disease. The economic health burden of IHD is substantial. In patients with old myocardial infarction (OMI), the extent of viable myocardium (VM) directly affects the short...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-017-9626-3

    authors: Jamiel A,Ebid M,Ahmed AM,Ahmed D,Al-Mallah MH

    更新日期:2017-07-01 00:00:00

  • Systolic heart failure in the elderly: optimizing medical management.

    abstract::The aging population with hypertension and coronary artery disease is rapidly increasing worldwide and develops heart failure (HF). A wide range of pharmacotherapeutic drugs are recommended in the HF management guidelines. For the most part, these recommendations are based on the results of studies in the younger popu...

    journal_title:Heart failure reviews

    pub_type: 杂志文章,评审

    doi:10.1007/s10741-011-9282-y

    authors: Man JP,Jugdutt BI

    更新日期:2012-09-01 00:00:00